MedPath

Management of severe facial pain using nerve block technique.

Not yet recruiting
Conditions
Other disorders of facial nerve,
Registration Number
CTRI/2019/01/017154
Lead Sponsor
PGIMER Chandigarh
Brief Summary

Trigeminal neuralgia (TGN) is characterized by the sudden onset of recurrent severe pain in trigeminal nerve distribution.The condition is severely disabling with impaired quality of life. Idiopathic TGN is difficult to treat by medications and interventional therapy may be required in 25-30% of patients. Trigeminal nerve block is usually performed for the relief of severe refractory pain of TGN by using landmark technique or under fluoroscopy guidance. The ultrasound-guided trigeminal nerve block via pterygopalatine fossa has been demonstrated in few case reports and found to be effective in patients with refractory trigeminal neuralgia and atypical facial pain. Therefore, the present study has been planned to evaluate the feasibility and effectiveness of ultrasound-guided trigeminal nerve block via pterygopalatine fossa for the management of idiopathic trigeminal neuralgia. In this study, 40 consecutive patients of refractory trigeminal neuralgia will receive trigeminal nerve block with 4 mL of bupivacaine 0.25% and 40 mg triamcinolone in the pterygopalatine fossa using ultrasound guidance. The patients will be followed up for 3 months to assess global pain relief and reduction in analgesic medications. Any adverse effect, patients’ satisfaction, and the number of patients having effective pain relief for 3 months will be recorded.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

40 consecutive adult patients of idiopathic trigeminal neuralgia resistant to pharmacological treatment will be included.

Exclusion Criteria

Allergy to local anesthetics or steroids, infection, coagulopathy, and pregnancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patients will be asked to rate their 24-hour global pain experience including severity, duration, frequency of the episodes, and to report it as a percentage of global pain reliefat 2 weeks, 1 month, 2 month and 3 months after procedure
Secondary Outcome Measures
NameTimeMethod
Duration of procedure, complications and success rateduring and after the procedure and at 1, 2 and 3 months

Trial Locations

Locations (1)

Post Graduate Institute of Medical Education and Research

🇮🇳

Chandigarh, CHANDIGARH, India

Post Graduate Institute of Medical Education and Research
🇮🇳Chandigarh, CHANDIGARH, India
Dr Neerja Bharti
Principal investigator
9915575145
bhartineerja@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.